P.hd in Reproductive Health Research:Developing agents for prevention of estrogen deficiency and age related bone loss, but lacking carcinogenic effect of estrogen on the endometrium and breast, in addition to being free from other estrogen-related health hazardsCentral Drug Research Institute
Price on request
Among the thirty eight laboratories functioning under the wings of CSIR, CDRI is considered as the best one. CDRI uses latest technology and techniques to develop drugs, vaccination and diagnostics.
The world population is rising steeply and by 2050 it will be 9 billion and by 2016 it will be 1264 million. As per WHO, the annual abortion rate is 46 million and this is the scenario of most of the developing countries. The Government of India is concentrating on Reproductive Health Research Program.
This programme is focused to design and synthesize novel molecules/isolate from natural sources and to develop female or male contraceptives, spermicides with anti-STI properties, agents for the management of osteoporosis, breast cancer and benign prostatic hyperplasia, evaluate traditional remedies for fertility regulation and endocrine disorders